Atlanthera is a drug discovery company that specializes in developing therapies for bone diseases and bone cancer. The company is dedicated to advancing bone-targeted drug delivery systems, aiming to provide effective treatments for bone cancer and its metastases. Atlanthera's approach is centered on the innovative delivery of anti-cancer drugs specifically to bone tissues, which is crucial for enhancing the efficacy of treatments and minimizing side effects. The company boasts a highly qualified team and a network of globally recognized experts, positioning itself as a leader in this specialized field.

The company's pipeline includes several promising compounds targeting inflammation and oncology. Notable products in development include Ibuprofen and Prednisolone for inflammation and pain management, as well as Methotrexate and an Ifosfamide analog for oncology applications. Additionally, Atlanthera is working on a lead compound specifically designed for the treatment of bone cancer, highlighting its commitment to addressing critical needs in cancer therapy. Through its focused research and development efforts, Atlanthera aims to make significant contributions to the treatment landscape for bone-related diseases.

France

Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug 
www.atlanthera.com

ATLANTHERA

Company Details